Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III head-to-head study of TLL-018 versus tofacitinib monotherapy in active rheumatoid arthritis with inadequate response or intolerance to biologic DMARDs
CTR20232662Phase 3Completed
- Sponsor
- Highlight Pharmaceutical
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of girocitinib, tofacitinib in rheumatoid arthritis (RA), sponsored by Highlight Pharmaceutical. Started Nov 2023; status: completed.
02
Drugs
girocitinibtofacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20232662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232662.